All Articles

InfiMaker's new K1 desktop CNC combines true 5-axis machining with AI software, aiming to disrupt manufacturing. But can it deliver on its Kickstarter promise?

A traditional construction firm is set to become a pure-play AI robotics company on the NYSE. Why is JFB betting it all on XTEND's autonomous technology?

MetalCloak launches a new Tacoma suspension lineup, moving beyond simple lifts to offer three distinct, engineered systems for every type of owner.

Two Harbors fires back at a "baseless" lawsuit from UWM, exposing a financial firestorm centered on a massive derivatives loss and a failed merger.

COSCIENS Biopharma boasts a dramatic financial turnaround, but its strategic move to exit SEC oversight shifts the risk-reward calculus for investors.

HCIactive's 'Human Experience Engineering' promises an AI-driven fix for healthcare's notorious complexity. But can it earn trust in a crowded, high-stakes field?

As students face a choice between their health and education, one foundation offers direct aid. But does this agile approach mask a deeper systemic failure?

RBC and BMO's $2 billion sale of Moneris isn't just a big payday. It's a strategic retreat from a complex market, fueling a new chapter for Canadian commerce.

With new HKEX rules mandating rigorous board reviews, companies are at a crossroads. Specialist firms like GreenCo offer a path beyond compliance.

A family-owned filter maker's acquisition of a century-old supplier isn't just a deal; it's a masterclass in operational expansion and customer retention.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Jatagan Security's new UL Solutions verification for its reporting process could finally bring clarity to an industry plagued by unsubstantiated claims.

CanNor's latest funding is not just about infrastructure; it's a strategic play on Indigenous-led economic sovereignty and the future of Canada's North.

Shareholders have approved Fairfax Financial's buyout of Andrew Peller Ltd., ending its public chapter. This isn't just a deal; it's a strategic uncorking.

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

SINTX Technologies is shifting from R&D to sales, but its ambitious med-tech goals are balanced by a precarious financial reality. Is this a blueprint for resilience?

Black Rock Coffee Bar reports a stellar quarter with 25% revenue growth, but a deeper look reveals the complex challenges of rapid expansion in a competitive market.

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.